SubHero Banner

RotaTeq® (rotavirus vaccine, live, oral, pentavalent) – Expanded indication

February 23, 2017 – The FDA approved Merck’s RotaTeq (rotavirus vaccine, live, oral, pentavalent), to include prevention of rotavirus gastroenteritis in infants and children caused by type G9 when administered as a 3-dose series to infants between the ages of 6 – 32 weeks.

Download PDF